These findings indicate that utilizing clock-targeting small molecules to lower BMAL1::CLOCK activity and inhibit CSCs (central serous chorioretinopathy) may be a successful tactic for improving cellular sensitivity to non-targeted conventional therapy [252]. The gene discussed is CLOCK; the disease is central serous retinopathy.